logo
Twitter
Discord
Email
logo
SOPHiA GENETICS SA

SOPHiA GENETICS SA

NASDAQ•SOPH
CEO: Dr. Jurgi Camblong M.B.A., Ph.D.
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Listing Date: 2021-07-23
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
Contact Information
La PiEce 12, Rolle, 1180, Switzerland
41-21-694-10-60
www.sophiagenetics.com
Market Cap
$363.66M
P/E (TTM)
-4.8
47.3
Dividend Yield
--
52W High
$5.70
52W Low
$2.58
52W Range
89%
Rank63Top 94.0%
1.8
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 1.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q3 2025 Data

Revenue

$19.46M+22.77%
4-Quarter Trend

EPS

-$0.30+7.14%
4-Quarter Trend

FCF

-$8.90M-6.13%
4-Quarter Trend

2024 Annual Earnings Highlights

Key Highlights

Revenue Growth Solidifies Total revenue reached $65.17M USD for 2024, marking a 4% increase over the prior period.
Customer Base Expansion Core Genomics Customers grew to 472 as of year-end 2024, reflecting continued momentum in recurring revenue base.
Operating Loss Decreased Net loss for the year improved by 21%, totaling $62.49M USD for the fiscal year ended December 31, 2024.
Platform Analysis Volume Rises Platform analysis volume increased 11% to 352,628 in 2024, driven by existing customer usage and new onboarding.

Risk Factors

Gross Margin Faces Headwinds Gross margin decreased to 67% in 2024, primarily due to increased computational and storage-related costs.
Net Dollar Retention Declines Net Dollar Retention fell to 104% in 2024 from 130% in 2023, indicating slower revenue growth from existing base.
Continued Operating Cash Use Net cash used in operating activities was $42.82M USD for 2024; future funding relies on capital raising efforts.
Regulatory Approval Uncertainty Commercial potential is limited by uncertainty in obtaining necessary FDA clearance or approval for IVD applications.

Outlook

Platform Innovation Investment Strategy includes continued investment in scientific innovation to bring new features and expand multimodal capabilities.
Focus on U.S. Market Penetration Growth strategy targets worldwide customer adoption, with significant investment planned to scale direct sales force in U.S.
Expand Biopharma Offerings Intend to leverage platform to drive biopharma adoption across discovery, development, and deployment value chain segments.
Grow Industry Collaborations Establish new collaborations with instrument and service providers to enhance platform adoption and solution breadth.

Peer Comparison

Revenue (TTM)

TruBridge, Inc.TBRG
$349.88M
+3.6%
Definitive Healthcare Corp.DH
$242.28M
-5.3%
National Research CorporationNRC
$139.10M
-3.5%

Gross Margin (Latest Quarter)

Voyager Therapeutics, Inc.VYGR
100.0%
+0.0pp
Definitive Healthcare Corp.DH
84.9%
+6.7pp
SOPHiA GENETICS SASOPH
66.3%
-0.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
NRC$477.39M29.167.8%59.0%
SLP$419.85M-6.5-45.5%0.4%
SOPH$363.66M-4.8-93.9%38.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.1%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 3, 2026
|
EPS:-$0.20
|
Revenue:$20.49M
Reports
All Years

  • Form 20-F - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 4, 2025|
    Revenue: $65.17M+4.5%
    |
    EPS: $-0.95+22.1%
    Miss

  • Form 20-F - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 5, 2024|
    Revenue: $62.37M+31.1%
    |
    EPS: $-1.22+10.3%
    Miss

  • Form 20-F - FY 2022

    Period End: Dec 31, 2022|Filed: Mar 7, 2023|
    Revenue: $47.56M+17.6%
    |
    EPS: $-1.36-18.3%
    Beat

  • Form 20-F - FY 2021

    Period End: Dec 31, 2021|Filed: Mar 15, 2022|
    Revenue: $40.45M+42.4%
    |
    EPS: $-1.15-85.5%
    Beat